Among the major targets found by the network work are PIK3R1 and PTK2, AKT1 and EGFR, AKR1C3 and IGF1R, CDK1 and CYP19A1 — genes tied to oxidative stress, inflammation in the nervous system, apoptosis and the survival of neurons.
Visual summary · Journal of Innovations in Pharmaceutical and Biological Sciences
In Silico Elucidation of Molecular Mechanisms of Luteolin and Gramine against Parkinson’s Disease
Shaikh Sahil Asif, Syed Izhan, Shaikh Mehmood Dawood
- Editor approved · 16 Nov 2026
- June 2026
- DOI 10.56511/jipbs.2026.13105
The question
Through which targets and pathways might Luteolin and Gramine act in Parkinson's disease?
- Parkinson's disease worsens over time: dopaminergic neurons are lost, with oxidative stress, failing mitochondria, inflammation in the nervous system and clumping of α-synuclein.
- Plant chemicals have drawn attention for protecting nerve cells by acting on several targets at once.
What was done
Twocompounds studied: Luteolin and Gramine
GeneCardssource of the disease-linked genes
STRINGand Cytoscape, to assess shared targets
- The study set out to judge the therapeutic mechanisms of the two compounds against the disease, joining network pharmacology to molecular docking.
- Likely targets of Luteolin and of Gramine were found with SwissTargetPrediction and with PubChem; the genes tied to the disease came from GeneCards.
- Targets common to both sides were assessed with STRING and Cytoscape, then enriched for Gene Ontology terms and KEGG pathways.
Key findings
Finding 1 of 3
Major targets
named by the network work include PIK3R1, AKT1 and EGFR
Finding 2 of 3
Dopaminergic
synapse signalling played a substantial role
By the KEGG analysis, signalling at the dopaminergic synapse played a substantial part.
Finding 3 of 3
-7.6 kcal/mol
Luteolin bound PTK2 more tightly than Levodopa or Gramine
In the docking work Luteolin bound PIK3R1 at -7.4 kcal/mol; at PTK2 it reached -7.6 kcal/mol, better than Levodopa and better than Gramine.
Why it matters
- The authors say the data imply that the two compounds have effects that protect nerve cells in Parkinson's disease, by modulating many targets and pathways.
- The work joined network pharmacology to molecular docking, with shared targets assessed in STRING and Cytoscape.
How to cite
Shaikh Sahil Asif, Syed Izhan, Shaikh Mehmood Dawood. In Silico Elucidation of Molecular Mechanisms of Luteolin and Gramine against Parkinson’s Disease. Journal of Innovations in Pharmaceutical and Biological Sciences. 2026;13(01):35-44. https://doi.org/10.56511/jipbs.2026.13105
- The article at doi.org (the publisher's page and PDF)
- The article on the journal's site
- The journal at the ISSN Portal (ISSN 2349-2759)